10-K: Sunshine Biopharma Reports Full Year 2023 Results, Revenue Surges Following Nora Pharma Acquisition

Sunshine Biopharma's 2023 revenue significantly increased due to the inclusion of a full year of sales from its subsidiary, Nora Pharma, though the company still reported a net loss.

Summary

• Sunshine Biopharma reported a net loss of $4,506,044 for the year ended December 31, 2023, compared to a net loss of $26,744,440 in 2022.
• The company's revenue increased substantially to $24,092,787 in 2023 from $4,345,603 in 2022, primarily due to the acquisition of Nora Pharma.
• Cost of sales rose to $15,753,616 in 2023 from $2,649,028 in 2022, reflecting the increased sales volume.
• General and administrative expenses decreased to $13,124,470 in 2023 from $28,697,325 in 2022, but excluding a one-time impairment of goodwill in 2022, G&A expenses increased by $2,753,864 in 2023.
• The company had interest income of $811,974 in 2023, compared to $518,650 in 2022, and interest expense of $137,308 in 2023, compared to $39,412 in 2022.
• As of December 31, 2023, the company had cash and cash equivalents of $16,292,347.
• The company completed a private placement of common stock and warrants in May 2023 for net proceeds of approximately $4.1 million.
• Net cash used in operations was $8,775,111 in 2023, compared to $5,248,358 in 2022, due to the expansion of Nora Pharma's drug portfolio.
• The company believes its existing cash will be sufficient to fund operations for the next 24 months, but anticipates needing to raise additional capital in the future.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth is positive, the continued net loss and need for future capital raises temper the overall sentiment. The company faces significant competition and regulatory hurdles, adding to the uncertainty.

Positives

• The company experienced a substantial increase in revenue due to the acquisition of Nora Pharma.
• The net loss decreased significantly compared to the previous year.
• The company has a solid cash position of over $16 million.
• The company believes it has sufficient cash to fund operations for the next 24 months.

Negatives

• The company still reported a net loss for the year.
• Operating expenses increased when excluding a one-time impairment of goodwill in 2022.
• The company anticipates needing to raise additional capital in the future.
• The company's research and development of Adva-27a was paused due to unfavorable in vitro results.

Risks

• The company has incurred significant losses and may not achieve profitability.
• The generic pharmaceutical business is subject to volatility and supply chain issues.
• The company faces intense competition in the generic drug market.
• The company may not receive required regulatory approval for its non-generic pharmaceutical product candidates.
• The company will require additional funding to satisfy future capital needs.
• The company's stock price has been volatile and may be delisted from Nasdaq if it does not meet listing requirements.
• The company's business is subject to the effects of adverse publicity.
• The company's manufacturing and third-party fulfillment activities are subject to certain risks.

Future Outlook

The company believes its existing cash will be sufficient to fund operations for the next 24 months, but anticipates needing to raise additional capital in the future for research and development and expansion of generic pharmaceutical operations.

Management Comments

• Management believes that additional treatment options such as the one they are developing which targets a different part of the virus could potentially form an important component of the range of anti-coronavirus treatment options available to attending physicians.
• Management determined that there are inherent uncertainties related to these factors as well as significant risks to cash flows due to ongoing geopolitical and geo-economics conflicts, making the discounted cash flow model unreliable.

Industry Context

The Canadian generic pharmaceuticals market is valued at approximately $9.7 billion USD in 2023, with the top 3 players holding approximately 50% of the market. Sunshine Biopharma, through Nora Pharma, is a relatively new player but has shown rapid sales growth. The company also faces competition from major pharmaceutical companies in the development of anticancer and antiviral drugs.

Comparison to Industry Standards

• The Canadian generic pharmaceutical market is dominated by a few large players, with the top 3 holding approximately 50% of the market share, making it a competitive landscape for new entrants like Nora Pharma.
• Sunshine Biopharma's R&D efforts in oncology and antivirals place it in competition with major pharmaceutical companies like Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb, and Novartis, all of which have significantly greater resources.
• The company's development of a PLpro inhibitor for SARS-CoV-2 is in competition with established treatments like Paxlovid, Molnupiravir, and Remdesivir, which have already received regulatory approval and are being used in clinical practice.
• The company's OTC product, Essential 9, is positioned in a highly competitive market with numerous manufacturers and retailers, but the company believes its unique formulation may provide a competitive advantage.

Management Changes

Corporate Governance

Related Party Transactions

• The company redeemed 990,000 shares of Series B Preferred Stock from Dr. Steve Slilaty, the CEO, in 2022.
• The company sold 20,000 shares of Series B Preferred Stock to Dr. Slilaty in February 2024.
• The company sold 100,000 shares of Series B Preferred Stock to Dr. Slilaty in March 2024.

Stakeholder Impact

• Shareholders face the risk of stock dilution due to potential future capital raises.
• Employees may be affected by potential workforce reductions if the company fails to secure additional funding.
• Customers of Nora Pharma may benefit from the expansion of the drug portfolio.
• Suppliers may experience increased demand due to the company's growth.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company plans to continue developing its proprietary drug candidates, including K1.1 mRNA and SBFM-PL4.
• The company intends to launch 32 additional generic drugs in 2024 and 2025.
• The company will seek to regain compliance with Nasdaq listing requirements, including a potential reverse stock split.
• The company will continue to monitor and manage cybersecurity risks.

Key Dates

Keywords

pharmaceutical, generic drugs, oncology, antivirals, Nora Pharma, revenue, net loss, clinical trials, FDA, mRNA, COVID-19, warrants, reverse stock split, intellectual property, capital raise